Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1225 of 2051 entries
View as:

A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)

Phase: N/A Priority: Normal
NCT ID: NCT06609161 Org: User:
Start: 07/16/24 End: 08/08/24 Due: 08/08/25

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Phase: N/A Priority: Normal
NCT ID: NCT03036488 Org: User:
Start: 03/07/17 End: 09/30/25 Due: 09/30/26

Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)

Phase: N/A Priority: Normal
NCT ID: NCT03326986 Org: User:
Start: 11/10/17 End: 12/17/18 Due: 12/17/19

A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)

Phase: N/A Priority: Normal
NCT ID: NCT00894114 Org: User:
Start: 05/31/03 End: 06/30/09 Due: 06/30/10

Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00337428 Org: User:
Start: 05/31/06 End: 05/31/07 Due: 05/31/08

A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)

Phase: N/A Priority: Normal
NCT ID: NCT06615869 Org: User:
Start: 01/20/23 End: 03/15/23 Due: 03/15/24

A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009)

Phase: N/A Priority: Normal
NCT ID: NCT02835118 Org: User:
Start: 07/31/09 End: 10/31/09 Due: 10/31/10

A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00769132 Org: User:
Start: 08/03/07 End: 11/06/07 Due: 11/06/08

Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

Phase: N/A Priority: Normal
NCT ID: NCT00993187 Org: User:
Start: 05/04/10 End: 10/29/13 Due: 10/29/14

Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)

Phase: N/A Priority: Normal
NCT ID: NCT00704951 Org: User:
Start: 07/31/08 End: 06/30/11 Due: 06/30/12

A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia

Phase: N/A Priority: Normal
NCT ID: NCT00124722 Org: User:
Start: 12/31/04 End: 07/31/07 Due: 07/31/08

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

Phase: N/A Priority: Normal
NCT ID: NCT03099161 Org: User:
Start: 06/27/17 End: 02/21/18 Due: 02/21/19

A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine

Phase: N/A Priority: Normal
NCT ID: NCT00000628 Org: User:
Start: - End: - Due: -

Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)

Phase: N/A Priority: Normal
NCT ID: NCT04678505 Org: User:
Start: 02/10/21 End: 04/27/21 Due: 04/27/22

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Phase: N/A Priority: Normal
NCT ID: NCT04586231 Org: User:
Start: 02/25/21 End: 02/11/27 Due: 02/11/28

A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)

Phase: N/A Priority: Normal
NCT ID: NCT00552929 Org: User:
Start: 10/04/05 End: 09/15/06 Due: 09/15/07

Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)

Phase: N/A Priority: Normal
NCT ID: NCT00822237 Org: User:
Start: 01/31/09 End: 12/31/09 Due: 12/31/10

Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)

Phase: N/A Priority: Normal
NCT ID: NCT00451217 Org: User:
Start: 11/17/05 End: 03/06/06 Due: 03/06/07

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)

Phase: N/A Priority: Normal
NCT ID: NCT01651936 Org: User:
Start: 08/29/12 End: 10/08/13 Due: 10/08/14

Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)

Phase: N/A Priority: Normal
NCT ID: NCT01076088 Org: User:
Start: 11/15/10 End: 12/24/12 Due: 12/24/13

A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)

Phase: N/A Priority: Normal
NCT ID: NCT00849680 Org: User:
Start: 04/30/03 End: 02/28/10 Due: 02/28/11

Study of Diquafosol Tetrasodium Ophthalmic Solution in Subjects With Dry Eye Disease

Phase: N/A Priority: Normal
NCT ID: NCT00403975 Org: User:
Start: 06/30/04 End: 11/30/04 Due: 11/30/05

A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

Phase: N/A Priority: Normal
NCT ID: NCT02335411 Org: User:
Start: 02/03/15 End: 07/23/21 Due: 07/23/22

Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)

Phase: N/A Priority: Normal
NCT ID: NCT00750919 Org: User:
Start: 10/07/08 End: 03/10/10 Due: 03/10/11

Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

Phase: N/A Priority: Normal
NCT ID: NCT01945294 Org: User:
Start: 10/10/13 End: 11/04/15 Due: 11/04/16